Indikationen zur Insulintherapie bei Typ-2-Diabetes – Wahl des Therapie-
Regimes nach individuellen Kriterien

Thorsten Siegmund
aus BDI aktuell 7/2007

1 Hauner H. The costs of diabetes mellitus and its complications in Germany. Dtsch Med Wochenschr 2006; 131: 240-242


9 Haak T, Tiengo A, Draeger E. et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005; 7: 56-64


16 Janka HU, Pleve G, Riddle MC. et al.. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-259

17 Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885


19 Siegmund T, Weber S, Blankenfeld H. et al.. Comparison of insulin glargine versus NPH insulin in people with Type 2 Diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin. Submitted